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The mitogenic effect of human fibrinogen on the 
hemopoietic cell lines Raji and JM is mediated by a 
specific receptor with biochemical and functional prop- 
erties different from those of the platelet fibrinogen 
receptor, the glycoprotein complex IIb-IIIa (Levesque, 
J. P., Hatzfeld, A., and Hatzfeld, J. (1986) Proc. Nutl. 
Acad. Sci. U. S. A. 83, 6494-6498; Levesque, J. P., 
Hatzfeld, A., Hudry-Clergeon, G., Wilner, G. D., and 
Hatzfeld, J. (1987) J. Cell. Physiol. 232, 303-310). 
This work describes the identification of the mitogenic 
fibrinogen receptor (MFR) by two independent meth- 
ods, affinity chromatography and covalent cross-link- 
ing. Affinity chromatography of surface-labeled cell 
extracts on fibrinogen-Sepharose revealed a 94 f 2- 
kDa membrane protein that bound specifically to fi- 
brinogen-Sepharose only on cells that expressed the 
MFR. Its molecular mass was not modified after reduc- 
tion. This was confirmed by cross-linking fibrinogen 
to surface-labeled Raji cells using the cleavable cross- 
linkers, ethyleneglycobis(succinimidy1 succinate) and 
dithiobis(succinimidy1 propionate). Complexes be- 
tween fibrinogen and iodinated cell membrane proteins 
were immunoprecipitated by anti-fibrinogen antibod- 
ies. The biochemical cleavage of these immunoprecip- 
itated conjuguates gave rise to a 92 f 3-kDa membrane 
protein whose molecular mass was not modified after 
reduction. We conclude that fibrinogen binds specifi- 
cally to a 92-94-kDa MFR which does not belong to 
the integrin family. 
Human fibrinogen is a major plasma protein which is the 
main substrate for thrombin in the coagulation process and 
plays an active role in platelet aggregation (1) and wound 
healing (2). Platelet aggregation is initiated by fibrinogen 
binding to the activated glycoprotein complex IIb-IIIa (GP 
IIb-IIIa),’ the platelet fibrinogen receptor (3). This binding 
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cobis(succinimidy1 succinate); FCS, fetal caif serum; .IMDI$ Iscc&- 
modified Dulbecco medium; MFR, mitogenic fibrinogen receptor; 
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oride; SDS-PAGE, sodium dodecylsulfate-polyacrylamide gel electro- 
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involves the Arg-Gly-Asp sequences (4) and the COOH ter- 
mini of the y chains (5) of the fibrinogen molecule. The 
resulting clot is composed of platelets and various types of 
blood cells trapped in a three-dimensional matrix of cross- 
linked fibrin, fibronectin, and plasminogen (2). The clot is 
degraded by activated plasmin to generate fibrinogen frag- 
ments D and E (6). Fibrinogen and its fragments exert several 
effects on the cell types involved in wound healing. The 
binding of fibrinogen on fibroblasts and endothelial cells by 
its E domain may induce their migration (7, 8). Fragment D 
stimulates the production of monokines (9) and causes dis- 
organization of cultured vascular endothelial cells (10). Small 
peptides generated by the degradation of the fibrinogen Acu 
chain COOH-terminal end suppress T lymphocyte functions 
00 
Earlier studies from our laboratory described the in uitro 
mitogenic effect of human fibrinogen and its D fragments on 
human hematopoietic cells such as bone-marrow progenitors 
in serum-supplemented cultures and the lymphoblastoid cell 
lines Raji and JM in serum-free culture (12). This fibrinogen 
mitogenic effect was shown to be mediated by a specific 
membrane receptor with a Kd from 2.0 to 3.5 X 10m7 M (13). 
This receptor, depending on the cells which express it, can be 
induced by activation of adenylate cyclase or phosphoinositide 
breakdown (13). This mitogenic fibrinogen receptor (MFR) is 
different from the GP IIb-IIIa complex; the MFR recognizes 
neither the Arg-Gly-Asp sequences nor the COOH termini of 
the fibrinogen y chains implicated in GP IIb-IIIa/fibrinogen 
interaction (14). 
This report describes the identification of this MFR by 
affinity chromatography on fibrinogen-Sepharose and by co- 
valent ligand-receptor cross-linking. It was found to be a 92- 
94-kDa membrane protein that specifically binds fibrinogen. 
MATERIALS AND METHODS 
Reagents-Cell culture reagents were purchased from Aqual-Bio- 
chrom (Angoulime, France), culture dishes and flasks from CML 
(Nemours, France), fetal calf serum (FCS) from Flow Laboratories, 
Na’? from Amersham (Les Ulis, France), hirudin from Diagnostica- 
Stago (Asniires, France), aprotinin from Laboratoires Choay (Paris, 
France). ethvleneglvcobis(succinimidy1 succinate) (EGS) and di- 
thiobis(iucci&midji propionate) (DSP) from Pierce, molecular 
weight standard, human transferrin, bovine lactoperoxidase, oleic, 
linoleic and palmitic acids from Sigma, Pansorbin from Calbiochem, 
fatty acid-free bovine serum albumin from Miles, goat anti-human 
fibrinogen antibodies first from Miles and further from Sigma, 
AG501-X8(D) ion-exchange resin from Bio-Rad, and fluorescein- 
conjugated anti-mouse Fab fragments from Nordic Immunological 
Laboratories (Tilburg, Netherlands). P2, P4 (15), and M232’ mono- 
clonal antibodies were gifts from Drs. J. Brochier and A. Bernard, 
’ A. Bernard, personal communication. 
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respectively. Fibrinogen fragment E was a gift from Dr. G. D. Wilner 
(14). 
Cell Lines-Raji, JM, K562, and U937 cell lines were grown in 
suspension in RPMI-1640 medium supplemented with 1% L-gluta- 
mine (200 mM), 1% penicillin-streptomycin (10,000 units/l0 mg/ml) 
stock solutions, and 10% FCS. MFRs were down-regulated by cultur- 
ing Raji and JM cells for at least 48 h in RPM1 medium supplemented 
with 10% FCS and 50 pg/ml human fibrinogen. For down-regulation 
experiments, cells were cultured in Iscove-modified Dulbecco medium 
(IMDM) supplemented by 1% L-glutamine and penicillin-strepto- 
mycin stock solutions, 5 pg/ml iron-saturated human transferrin and 
1 mg/ml fatty acid-free bovine serum albumin deionized with AG501- 
X8(D) resin and reconstituted with 5 fig/ml oleic acid, 5 pg/ml linoleic 
acid, and 1 pg/ml palmitic acid (16). This medium will be referred to 
as “GTL medium.” Cells were collected for binding assays or covalent 
cross-linking when they reached a density of 5 x lo5 cells/ml. 
Fibrinogen-Nine-hundred ml of fresh human plasma were col- 
lected on 100 ml of 3.8% (w/v) trisodium citrate buffer containing 2 
mM phenylmethane sulfonyl fluoride (PMSF), 3 mM benzamidine, 1 
mM EDTA, 200 mM e-aminocaproic acid, 0.2% NaNa, 100 units/ml 
aprotinin, and 0.5 units/ml hirudin. Human fibrinogen was purified 
according to Kekwick et al. (17). All buffers were supplemented with 
2 mM PMSF, 100 units/ml aprotinin, and 0.5 units/ml hirudin. The 
fibronectin residue was removed on a gelatin-agarose column (18). 
The resulting fibrinogen, more than 99% pure, was iodinated by the 
chloramine-T method described by McConahey and Dixon (19) as 
modified by Marguerie et al. (3). 
Fibrinogen Binding Assay-Cells were washed three times in 
IMDM. One-hundred and seventy-p1 aliquots of suspension contain- 
ing 5 X lo6 cells/ml were incubated at 20 “C with 12.5 units/ml 
hirudin, 0.15 pM “‘I-fibrinogen. Fifty-HI samples of the mixture were 
removed after suitable times and transferred onto a double layer 
gradient as previously described (20). All determinations were per- 
formed in triplicate. The samples were centrifuged for 2 min at 12,000 
x g, the tips of the centrifuge tubes were cut off with a razor blade, 
and their contents were counted in an LKB y counter. 
Cell Surface Labeling-Cells (1.5 x 10’) were collected and washed 
three times in phosphate-buffered saline, resuspended in 5 ml of 
phosphate-buffered saline, and iodinated by the lactoperoxidase 
method (21). One ml of lactoperoxidase (1 mg/ml in phosphate- 
buffered saline), 37 MBq of Na’? and 100 ~1 of 0.12% hydrogen 
peroxide were mixed and gently vortexed every 30 s for 5 min; an 
additional 100 ~1 of 0.12% H,O, was then added, and the reaction 
was continued for a further 5 min. Cells were washed three times in 
IMDM prior to use. 
Coupling of Fibrinogen to CNBr-actiuated Sepharose-The proce- 
dure used was derived from that described by Matthias et al. (22). 
Fibrinogen (30 mg) was dialyzed against 0.1 M Na2HP04 buffer, pH 
7.8, containing 100 units/ml aprotinin and added to 1 g of CNBr- 
activated Sepharose previously washed with 100 ml of 1 mM HCl. 
Coupling occurred after an overnight incubation at 4 “C (yield 91%). 
A l-cm-diameter column was filled with the coupled fibrinogen- 
Sepharose and washed at 4 “C at a flow rate of 30 ml/h with the 
foliowing buffers: 1) 0.1 M Na2HP04, pH 7.8 (6 h); 2) ‘0.1 M Tris- 
H,PO,. 1 M NaCI. oH 8.6 (2 h): 3) 0.1 M Tris-HIPOd. 1 M NaCl. DH 
5.3 (2’h); 4) 0.1 M’NaHC&, c?i & glycine (24 h); 5j’IMDM (lib). 
All buffers contained 1 mM PMSF and 100 units/ml aprotinin. Six 
mg of fibrinogen fragment E were also coupled to 1 g of CNBr- 
activated Sepharose by the same method to provide a molarity of 
immobilized fragment E L&fold higher than that of immobilized 
intact fibrinogen. 
Affinity Chromatography on Fibrinogen-Sepharose-The fibrino- 
gen-Sepharose column was equilibrated with IMDM containing 50 
mM l-O-n-octyl-@-D-glucopyranoside at 20 “C. Surface-iodinatedcells 
were solubilized in IMDM containing 200 mM I-O-n-OCtyl-@-D-gh- 
copyranoside, 1 mM PMSF, and 100 units/ml aprotinin. The cell 
extract was centrifuged at 10,000 X g for 10 min and the supernatant 
immediately placed on the affinity column and left for 15 min after 
its complete penetration into the fibrinogen-Sepharose. The column 
was washed first with IMDM at a flow rate of 1 ml/h for 15 h. The 
remaining proteins bound to fibrinogen-Sepharose were eluted at a 
flow rate of 10 ml/h with IMDM containing 8 M urea or a combination 
of 3 M NaBr and 5 mM dodecyl+D-maltoside. All buffers contained 
1 mM PMSF and 100 units/ml of aprotinin. Five-hundred-p1 fractions 
were collected, and their absorbance at 280 nm and their radioactivitv 
were measured prior to analysis by SDS-PAGE. 
Chemical Cross-linking bv EGS and DSP-Iodinated receutors free 
I  I  
of contamination by labeled ligand were prepared by affinity labeling. 
Cells were washed three times in IMDM and resuspended at 5 x 10” 
cells/ml. One-ml aliquots were incubated for 30 min at 20 “C with 
12.5 units/ml hirudin and 0.15 pM labeled or unlabeled fibrinogen 
before adding EGS from a solution of 100 mM EGS extemporaneously 
prepared in dimethyl sulfoxide. One min later, the reaction was 
stopped by adding a lo-fold molar excess of ammonium acetate. A 
50-~1 aliquot was then taken to measure fibrinogen binding as de- 
scribed above. Preliminary experiments showed that the cross-linking 
reaction reached a plateau at EGS concentrations of 0.2-0.8 mM; 
concentrations above 1 mM produced nonspecific cross-linking which 
increased exponentially with EGS concentration (results not shown). 
Therefore, 0.4 mM EGS concentration was used. Then samples were 
washed three times in IMDM, and the final cell pellet was treated 
with 100 ~1 of 150 mM NaCl, 10 mM sodium phosphate buffer at pH 
7.4 containing 1% Triton X-100, 1% sodium deoxycholate, 1 mM 
PMSF, 1 mM EDTA, 0.1% NaNn, and 100 units/ml aprotinin (RIPA 
buffer). The cell extracts were centrifuged at 10,000 x ,g for 5 min to 
remove insoluble material. Fibrinogen-MFR conjugates were immu- 
noprecipitated by anti-fibrinogen polyclonal antibodies as described 
below. These immunoprecipitated covalent complexes were then dis- 
sociated by overnight incubation at 37 “C with 100 11 of 1 M hydrox- 
ylamine hydrochloride, pH 8.8 (23). Hydroxylamine was removed 
from samples by gel permeation chromatography on a Trisacryl GF 
05 M column (IBF, Villeneuve-La-Garenne, France), equilibrated with 
10 mM Tris-HCl, pH 7.3 buffer. Protein-containing samples were 
pooled, lyophilized, redissolved in one-tenth of the initial volume in 
electrophoresis buffer, and analyzed by SDS-PAGE. 
Experiments using DSP were performed under the same conditions 
except for dissociation of the MFR-fibrinogen covalent complexes. In 
this case, complexes were dissociated by a 30-min incubation in 10 
mM dithiothreitol, 10 mM Tris, pH 8.0 buffer, and further diluted 
with an equal volume of P-fold concentrated electrophoresis buffer. 
SDS-Polyacrylamide Gel Electrophoresis-SDS-PAGE was per- 
formed as described by Laemmli (24) using gels with a 5-12.5% 
acrylamide linear gradient. The protein standards were carbonic 
anhydrase (29 kDa), ovalbumin (45 kDa), bovine serum albumin (66 
kDa), phosphorylase b (97.4 kDa), B-galactosidase (116 kDa), and 
myosin (205 kca). Gels were stained with Coomassie Brillant Blue 
and autoradioaraDhed at -30 “C using Kodak Ortho-G films and 
Lanex Regulaginiensifying screens for-2 days to 1 week. Autoradi- 
ographs were analyzed on a Shimadzu CS-930 gel scanner. 
Zmmunofluorescence and Zmmunoprecipitation-Indirect immuno- 
fluorescence was performed according to Janossy et al. (25). Cells 
were washed three times in IMDM, resuspended at 5 x 10h cells/ml 
in IMDM supplemented with 0.2% bovine serum albumin and 0.2% 
NaN3, and loo-j11 aliquots were placed in 200-~1 microtiter wells. 
Twenty rg/ml specific monoclonal antibody was added to each well, 
and the plates were incubated for 10 min at room temperature. The 
cells were then washed three times at 4 “C in the incubation medium 
and incubated for 30 min at 4 “C with fluorescein-conjugated anti- 
mouse Fab fragments. The cells were washed four times at 4 “C and 
examined by epifluorescence microscopy. 
For immunoprecipitation experiments, loo-p1 aliquots of cell ex- 
tract complexes in RIPA buffer were preincubated for 30 min at 20 “C 
with 20 ~1 of Pansorbin. Supernatants were then collected and further 
incubated with 20 ~1 (1 ma/ml) of antibodv for 1 h at 37 “C. One- 
hundred ~1 of Pansorbin i&e added, incudation was continued for 
30 min at 20 “C, and the resulting immunoprecipitates were washed 
twice with RIPA buffer. The radioactivity of the precipitates was 
counted before they were analyzed on SDS-PAGE. 
RESULTS 
Affinity Chromatography of Raji, JM, and U937 Cell Ex- 
tracts on Fibrinogen-Sepharose-JM, Raji, and U937 cells 
were cultured with 10% of a FCS serum batch containing less 
than 5 pg/ml residual fibrinogen. Under these conditions, Raji 
and JM cells bound, respectively, 8 x lo4 and 4 X lo4 fibrin- 
ogen molecules/cell when lz51-fibrinogen was added at a con- 
centration of 0.15 PM, whereas U937 did not significantly bind 
fibrinogen. 
Extracts from radioiodinated JM and Raji cells, correspond- 
ing to 1.5 X 10’ cells, were chromatographed on a fibrinogen- 
Sepharose column. The only band which was strongly retained 
after washing by IMDM was at 93.6 + 1.4 kDa (n = 10) 
namely p94. Indeed, these eluates contained 84% of total 
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330 Identification of the Mitogenic Fibrinogen Receptor 
labeled membrane proteins but only 7% of the initial p94 
protein (Fig. 1). We had to use a strong dissociation agent 
such as 8 M urea or 3 M NaBr together with 5 mM dodecyl-/3- 
D-maltoside to elute the p94 protein bound to the fibrinogen- 
Sepharose matrix. In these urea or NaBr and dodecyl malto- 
side eluates obtained from Raji cell extracts, the p94 repre- 
sented 89% of the labeled proteins (Fig. 1). In Fig. 2, the 
fractions obtained by elution with 8 M urea were analyzed on 
a 7.5% SDS-PAGE under reducing and nonreducing condi- 
tions. The major membrane protein from JM and Raji cell 
urea eluates had an apparent molecular weight of 93,600 f 
1,600 (n = 10) under both reducing and nonreducing condi- 
tions. This p94 protein was absent from the 8 M urea eluates 
obtained by chromatography of U937 cell extracts; these cells 
1 2345678910 
kDa 
205- 
116- 
97- 
P64 
FIG. 1. Affinity chromatography on fibrinogen-Sepharose 
of Raji cell extract. 1.5 x 10’ Raji cells were labeled and chromat- 
ographed as described under “Materials and Methods.” Fractions 
were collected and analyzed by SDS-PAGE under reducing conditions 
on a 7.5% polyacrylamrde gel. Lane I represents the total Raji cell 
extract that was chromatographed. Lanes 2-9 are eluates obtained by 
washing the column with IMDM. Lane IO is the fraction eluted with 
3 M NaBr and 5 mM dodecyl-/-n-maltoside; similar results are ob- 
tamed with 8 M urea. 
J R U J R U 
._ - 
kDa 
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FIG. 2. Autoradiography of urea eluates obtained by affin- 
ity chromatography of JM (J), Raji (R), and U937 (V) cell 
extracts. Extracts from iodinated Raji, JM, and U937 cells were 
chromatographed on fibrinogen-Sepharose. Membrane proteins 
bound to the affinity column were eluted by 8 M urea as described 
under “Materials and Methods.” 8 M urea eluates were analyzed by 
SDS-PAGE under reducing (leftpanel) and nonreducing (rightpanel) 
conditions on a 7.5% polyacrylamide gel. 
MFR, 
1 2 3 
kDa 
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FIG. 3. Identification of labeled MFR by dissociation of the 
cross-linked complex between MFR and fibrinogen. Surface- 
labeled Raji cells were cross-linked to unlabeled fibrinogen with EGS 
and immunoprecipitated by anti-fibrinogen antibodies (lane I) or by 
BL13 (lane 2) before treatment with NH,OH. Lane 3 is a negative 
control in which surface-labeled cells were cross-linked to bovine 
serum albumin with EGS and immunoprecipitated by anti-fibrinogen. 
After cleavage by NH,OH of the immunoprecipitated cross-linked 
complexes (see “Materials and Methods”), samples were analyzed 
under reducing conditions on a 5-12.5% SDS-PAGE. 
do not bind fibrinogen. It was also absent from urea eluates 
of Raji cells whose MFRs had been previously down-regulated 
by culture in the presence of 10% serum and 50 pug/ml fibrin- 
ogen, conditions under which fibrinogen binding dropped to 
6% of the control. 
The specificity of p94 protein retention on fibrinogen- 
Sepharose was assessed by chromatographing Raji cell ex- 
tracts on fibrinogen fragment E-Sepharose. We have PI.+ 
ously shown that fragment E does not interact with the MFR 
(14). We observed that fragment E-Sepharose did not retain 
any membrane protein from Raji cell extracts using the same 
experimental procedure. 
Identification of the ““I-MFR by Cross-linking with EGS- 
Although various control experiments suggested that the p94 
protein detached by urea was the MFR, this elution was not 
specific. The identification of the p94 protein as the MFR 
was confirmed by immunoprecipitation of the covalent MFR- 
fibrinogen complexes with anti-fibrinogen antibodies. Sur- 
face-iodinated Raji cells were cross-linked to specifically 
bound fibrinogen by a cleavable cross-linker. EGS was chosen 
because its cleavage occurs independently of the presence of 
2-mercaptoethanol(23). Fig. 3 shows that the main membrane 
protein obtained after cleavage by hydroxylamine of the im- 
munoprecipitate is a 92 f 2 kDa protein (lane I). We have 
shown elsewhere that, at the concentration of fibrinogen used 
in this experiment, nonspecific fibrinogen binding to Raji 
cells represents 5-15% of the total binding (13, 14). This 
nonspecific binding could account for minor bands immuno- 
precipitated together with the 92-kDa protein. We checked 
that this protein was not precipitated when anti-fibrinogen 
antibodies were replaced by BL13 antibody (lane 2) which 
recognizes the CR2 complement receptor (26) or when iodi- 
nated Raji cells were cross-linked to bovine serum albumin 
instead of fibrinogen (lane 3). The 92-kDa protein extracted 
by covalent cross-linking was compared under reducing and 
nonreducing conditions (Fig. 4). Like the p94 protein obtained 
by affinity chromatography, its apparent molecular mass was 
not modified after reduction. 
MFR Expression and Fibrinogen Binding-When Raji cells 
were cultured in chemically defined GTL medium, the MFR 
could not be down-regulated by fibrinogen as occurs when 
cells are cultured with 10% FCS (56). In the experiment in 
Fig. 5, cells were first grown in GTL medium where they 
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12 3 4 
Q - kDa 
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FIG. 4. Molecular mass of MFR under nonreducing (lanes 1 
and 2) and reducing (lanes 3 and 4) conditions. MFR isolated 
by affinity chromatography of Raji cell extracts on fibrinogen-seph- 
arose is on lanes 1 and 3. MFR obtained by NHSOH cleavage of 
immunoprecipitated EGS-mediated conjugates between iodinated 
Raji cells and fibrinogen is on lanes 2 and 4. Analysis in the absence 
(lanes 1 and 2) and in the presence (lanes 3 and 4) of 5% 2- 
mercaptoethanol on a 7.5% polyacrylamide gel. 
A. 6. 
1 2 1 2 
kDa 
205- 
116- 
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FIG. 5. Isolation of 9-MFR from Raji cells before and 
after down-regulation. A, total membrane protein of surface- 
iodinated Raji cells before (1) and after (2) down-regulation. 1.5 x 
lo6 cells were solubilized in lOO-~1 RIPA buffer without sodium 
deoxycholate, and centrifuged at 10,000 X g for 5 min. Supernatants 
were analyzed on a 7.5% polyacrylamide gel under reducing condi- 
tions. B, surface-iodinated Raji cells before (1) and after (2) down- 
regulation were incubated with unlabeled fibrinogen and cross-linked 
with 0.4 mM DSP. Immunoprecipitated ‘?“I-MFR-fibrinogen com- 
plexes were dissociated with 10 mM dithiothreitol and analyzed by 
autoradiography after 7.5% polyacrylamide gel electrophoresis under 
reducing conditions. 
specifically bound 8.5 x lo4 fibrinogen molecules/cell when 
‘““I-fibrinogen was added to a final concentration of 0.15 pM. 
Under these conditions, a 92.kDa membrane protein was 
highly labeled after cell surface iodination (Fig. 5A, lane I). 
This protein was immunoprecipitated by anti-fibrinogen an- 
tibodies after cross-linking with specifically bound fibrinogen 
(Fig. 5B, lane I). When the same culture was grown with 10% 
FCS and 50 pg/ml fibrinogen to down-regulate the MFRs, 
lLSI-fibrinogen binding fell to 6% of that of the non-down- 
regulated control cells within 24 h. As shown in Fig. 5A, lane 
2, the down-regulation of fibrinogen binding on Raji cells 
suppressed 81% of the cell surface labeling of the 92-kDa 
protein as measured by gel scanning. Under these conditions, 
this protein was not detectable after cleavage by dithiothreitol 
of the specifically immunoprecipitated DSP-mediated com- 
plexes between fibrinogen and cell surface-labeled cells (Fig. 
5B, lane 2). We repeated this experiment with EGS instead 
of DSP and obtained quite similar results (not shown). 
Finally, we observed that the MFR was not immunoprecip- 
itated from U937, HL60, and K562 cells that do not bind 12’1- 
fibrinogen but was immunoprecipitated from JM cells which 
specifically bind lLiI-fibrinogen and also respond to its mito- 
genie effect (13). 
Absence of Immunoprecipitation of ““I-MFR by Monoclonal 
Antibodies against the GP ZZb-IIZa and CDl8-The MFR was 
shown to be different from the already well-defined platelet 
fibrinogen receptor GP IIb-IIIa. EGS-mediated complexes 
were treated with P2 and P4 monoclonal antibodies specific 
for GP IIb-IIIa (15) instead of anti-fibrinogen antibodies. 
These antibodies did not precipitate any labeled protein. We 
had previously checked by immunofluorescence that cross- 
linking of fibrinogen to platelets with EGS did not modify the 
binding of P2 and P4. 
The same procedure was used with M232, a monoclonal 
antibody directed against CD18, the p chain common to LFA- 
1, Mac-l/CRS, and gp150/95 antigens.’ This chain has a 
molecular mass of 95 kDa (27) which is similar to that of 
MFR but its molecular mass changes after reduction. No 
EGS-mediated complexes between MFR and fibrinogen were 
immunoprecipitated with this antibody. The absence of label- 
ing on Raji and JM cells by indirect immunofluorescence with 
M232 confirmed this result. 
DISCUSSION 
We have previously shown that fibrinogen has a mitogenic 
effect on hemopoietic progenitors and lymphoma-der:rved cell 
lines (12). This mitogenic effect is mediated by a specific 
receptor, the mitogenic fibrinogen receptor or MFR, that 
binds fibrinogen with a K,, of 2-3.5 X 10m7 M (13). As fibrin- 
ogen is continuously in excess in the hemopoietic organs, the 
mitogenic effect is regulated by the induction (13) or the 
down-regulation (56) of the receptor, depending on environ- 
mental conditions. The MFR is different from the GP IIb- 
IIIa complex which is the platelet fibrinogen receptor (14); in 
particular, Arg-Gly-Asp-containing peptides which inhibit fi- 
brinogen binding to GP IIb-IIIa, do not inhibit the binding of 
fibrinogen to MFRs. In this article, we identify the MFR as 
92-94-kDa protein which does not belong to the integrin 
family, which includes cell adhesion and substrate adhesion 
receptors (27). 
Two independent and complementary methods were used 
to isolate the MFR, affinity chromatography on fibrinogen- 
Sepharose and covalent cross-linking to fibrinogen by cleav- 
able cross-linkers. Both methods gave quite similar results. 
Analysis of the iodinated membrane proteins of Raji, JM, 
and U937 cells indicates that Raji and JM cells, which express 
the MFR, possess a 93.6-kDa surface protein which is absent 
on U937 (not shown) and MFR down-regulated Raji cells. A 
similar 93.6.kDa protein was identified by affinity chroma- 
tography on fibrinogen-Sepharose. Only 7% of this protein 
was eluted during column washes by IMDM after deposition 
of Raji and JM cell extracts whereas almost all the other 
membrane proteins were eluted. The last elution with 8 M 
urea or a combination of 3 M NaBr and 5 mM dodecyl-P-D- 
maltoside, although nonspecific, mainly detached the remain- 
ing 93.6-kDa protein. Other observations strengthened the 
possibility that p94 is the MFR. Indeed, we observed that 
urea eluted this protein only from cells which express the 
MFR and respond to the mitogenic effect of fibrinogen. More- 
over, the specific interaction between the p94 protein and 
immobilized ligand was not observed when fibrinogen was 
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332 Identification of the Mitogenic Fibrinogen Receptor 
replaced in the Sepharose matrix by fibrinogen fragment E, 
which does not bind to the MFR (14). 
The use of a specific eluant was not possible because high 
concentrations of fibrinogen would have clogged the column. 
High concentrations of specific peptides recognizing the bind- 
ing region of the MFR could not be used since the binding 
sequence of fibrinogen is still unknown. We have previously 
checked that RGD-containing peptides that compete with 
fibrinogen on the platelet fibrinogen receptors do not compete 
with fibrinogen on the MFR (14). We therefore used cross- 
linkers to covalently bind to fibrinogen and immunoprecipi- 
tated these complexes with anti-fibrinogen antibodies. In 
previous experiments, we used disuccinimidyl suberate, a non- 
cleavable cross-linker (not shown). We immunoprecipitated 
various complexes between MFR and single or cross-linked 
combinations of fibrinogen Aa, BP, and y chains. To avoid 
the difficulties in analysis of these complexes, we labeled the 
cell membrane proteins instead of the ligand and used two 
different cleavable cross-linkers which both gave the same 
results. This method was specific for a fibrinogen-binding 
protein. It confirmed all the results we obtained from the 
affinity purification: the MFR binding subunit is a 92-94- 
kDa protein whose apparent molecular mass does not change 
after reduction. It is present only on cells which respond to 
the fibrinogen mitogenic effect, such as JM and Raji cells 
under conditions in which the MFR is induced and not on 
HL60, K562, U937 cells or Raji cells after MFR down-regu- 
lation, which do not bind fibrinogen. We therefore have a 
perfect correlation between the ability to extract this 92-94- 
kDa protein and the functional expression of the MFR. 
In conclusion, we propose that the 92-94-kDa membrane 
protein of JM and Raji cells is the MFR, binding to fibrinogen 
by its D domain (14). This does not exclude the possibility of 
a regulatory subunit noncovalently associated with this 92- 
94-kDa protein. On a molecular mass basis, the MFR of Raji 
and JM cells differs from 1) receptors for extracellular matrix 
proteins such as laminin (28), collagen (29-31), and fibronec- 
tin whether or not they belong to the integrin family (31); 2) 
growth factor receptors such as platelet-derived growth factor 
(32), epithelial growth factor (33), interleukins (34-37), CSF- 
1 (38), GM-CSF (39), insulin (40), transferrin (41), endothe- 
lial cell growth factor (42), or insulin-like growth factor-II 
(43) receptors; 3) receptors and antigens present on various 
leukocytes, such as the three classes of IgG Fc fragment 
receptors (44), the tuftsin receptor (45), CR1 and CR2 com- 
plement receptors (46), and the lymphocyte function-associ- 
ated antigens LFA-2 and LFA-3 (47). 
The LFA-1, Mac-l/OKM-l/CR3 and p150,95 antigens are 
noncovalent heterodimers, (Y x @, with a common 95-kDa /3 
chain, namely CD18 (27, 48). Although CR3 has been de- 
scribed as binding fibrinogen and triggering monocyte differ- 
entiation (49, 50), the negative results obtained by immuno- 
fluorescence and immunoprecipitation with the M232 anti- 
body indicate that the MFR is different from the /3 subunit of 
these leukocytes adhesion proteins. Data from other labora- 
tories have confirmed this result, showing a low expression of 
this fi chain by JM cells (51) and the absence of CR3 on Raji 
cells (52). There are several other structural differences be- 
tween MFR and these other proteins. CD18 is rich in disulfide 
bonds and its apparent molecular mass increases under re- 
ducing conditions (48); no such increase was observed with 
the MFR. 
The MFR is different from the GP IIb-IIIa in that it does 
not contain glycoprotein IIb. Furthermore, the monoclonal 
antibodies P2 and P4 (15) do not bind to JM and Raji cells 
and do not immunoprecipitate the MFR. These observations 
are in agreement with the fact that both Arg-Gly-Asp-con- 
taining peptides and antibodies against the COOH terminus 
of the fibrinogen y chain are unable to inhibit the binding of 
‘251-fibrinogen to Raji and JM cells (4,5,14). Hence, the MFR 
is probably not a member of the integrin family that includes 
GP IIb-IIIa, the vitronectin and the fibronectin receptors, 
and the LFA-1, Mac-l/OKM-l/CR3, and p150,95 antigens 
(27). 
Recent data from Barsigian et al. (53) have shown that 
hepatocytes bind fibrinogen via a receptor which is inhibited 
by fibrinogen fragment D and not by fragment E or Arg-Gly- 
Asp-containing peptides. In spite of these similarities, this 
hepatocyte receptor is unlikely to be the MFR since these 
interactions differ in their divalent cation dependence and 
reversibility (13, 53). 
This MFR may be important in human hemopoiesis. In- 
deed, preliminary results from our laboratory indicate that 
fibrinogen synergizes interleukin-3 in the proliferation of 
hemopoietic progenitors. This effect is independent of cell 
adhesion on the fibrinogen matrix. In long-term bone marrow 
cultures, fibrinogen promotes self-renewal of granulocyte- 
monocyte progenitors for 14 weeks instead of 7 weeks in the 
absence of fibrinogen (12). 
Considering these data, fibrinogen can be compared with 
C3, the third component of human complement. Indeed, these 
two major plasma proteins both bind to low affinity receptors 
which are fully saturated at plasma concentrations of fibrin- 
ogen and C3. Both proteins have two distinct binding do- 
mains. One domain binds to a mitogenic receptor and the 
other to an adhesion receptor that are, respectively, the MFR 
and the GP IIb-IIIa for fibrinogen (14), the CR2 and CR3 
receptors for C3 (54). A third extracellular matrix protein, 
laminin, was recently shown to trigger these two effects via 
two distinct receptors that recognize two distinct domains of 
the laminin molecule (55). 
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